- Home
- JLS vs TCRX Comparison
JLS vs TCRX Comparison
Compare JLS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- TCRX
- Stock Information
- Founded
- JLS 2009
- TCRX 2018
- Country
- JLS United States
- TCRX United States
- Employees
- JLS N/A
- TCRX N/A
- Industry
- JLS Investment Managers
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- JLS Finance
- TCRX Health Care
- Exchange
- JLS Nasdaq
- TCRX Nasdaq
- Market Cap
- JLS 97.1M
- TCRX 82.1M
- IPO Year
- JLS N/A
- TCRX 2021
- Fundamental
- Price
- JLS $18.79
- TCRX $1.93
- Analyst Decision
- JLS
- TCRX Strong Buy
- Analyst Count
- JLS 0
- TCRX 6
- Target Price
- JLS N/A
- TCRX $9.50
- AVG Volume (30 Days)
- JLS 26.6K
- TCRX 574.8K
- Earning Date
- JLS 01-01-0001
- TCRX 08-11-2025
- Dividend Yield
- JLS 9.33%
- TCRX N/A
- EPS Growth
- JLS N/A
- TCRX N/A
- EPS
- JLS N/A
- TCRX N/A
- Revenue
- JLS N/A
- TCRX $4,421,000.00
- Revenue This Year
- JLS N/A
- TCRX $159.20
- Revenue Next Year
- JLS N/A
- TCRX N/A
- P/E Ratio
- JLS N/A
- TCRX N/A
- Revenue Growth
- JLS N/A
- TCRX N/A
- 52 Week Low
- JLS $15.48
- TCRX $1.02
- 52 Week High
- JLS $17.97
- TCRX $7.44
- Technical
- Relative Strength Index (RSI)
- JLS 53.48
- TCRX 63.03
- Support Level
- JLS $18.63
- TCRX $1.75
- Resistance Level
- JLS $19.06
- TCRX $1.96
- Average True Range (ATR)
- JLS 0.16
- TCRX 0.14
- MACD
- JLS -0.05
- TCRX 0.01
- Stochastic Oscillator
- JLS 37.21
- TCRX 94.00
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.